Join Richmond Pharmacology at this year s 10th Annual Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), taking place on June 26-29 in Budapest, Hungary.The Congress will focus on key research and therapeutic areas, related challenges and latest achievements with the help of distinguished invited speakers, opinion leaders, experts and the upcoming future generation of clinical pharmacologists.We invite all attendees to join Richmond Pharmacology s Medical Director and Co-Founder Dr Ulrike Lorch at her presentation titled  frThe Use of Adaptive Study Design in Early Phase Clinical Research  scheduled for Day one, Session one at 10am.  For the full Scientific Programme of EACPT Congress please click here.In the last several years the interest in Adgaptive Study Design is evident from the growing amount of clinical research employing this model in the mid to later stages of medicines development.  Dr Lorch s presentation will describe where this design is of benefit to the conduct of First into Human and Early Phase Combination Studies and compare adaptive and conventional study design.  Little has been published on the practical application and merits of adaptive study design in Early Phase Clinical Research, so this presentation offers attendees a chance to learn more about the subject.If you would like to meet with Dr Ulrike Lorch, Richmond Pharmacology s CEO Dr Jorg Taubel.In the last several years the interest in Adaptive Study Design is evident from the growing amount of clinical research employing this model in the mid to later stages of medicines development.  Dr Lorchinfo@richmondpharmacology.com in advance to arrange a face-to-face meeting and discuss how Richmond Pharmacology can assist you with your current challenges.We hope to see you in Budapest to learn more about Richmond Pharmacology and enjoy one of Europe�s most lively cultural destinations.

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event